Sisram Medical Delivers Solid 2026 Interim Results Injectables Business Fuels Rapid Growth as APAC Drives International Revenue Expansion HONG KONG, August 19, 2026 -- Sisram Medical Ltd (the “Company” or “Sisram”, 1696.HK; together with its…
Sisram Medical Delivers Solid 2026 Interim Results
Injectables Business Fuels Rapid Growth as APAC Drives International Revenue Expansion
HONG KONG, August 19, 2026 -- Sisram Medical Ltd (the “Company” or “Sisram”, 1696.HK;
together with its subsidiaries collectively referred to as the “Group”), a global wellness group
offering Energy-Based Devices (“EBD”), injectables, and other complementary solutions, today
announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the
“Reporting Period”). During the Reporting Period, the Company achieved steady overall growth,
propelled by accelerating momentum in its Injectables business and robust performance across the
APAC region. These two growth drivers effectively mitigated headwinds in North America and
broader macro uncertainties, underscoring the Company’s operational stamina and strategic
prudence.
FINANCIAL HIGHLIGHTS
•
•
•
•
•
•
•
Revenue was US$171.4 million, representing an increase of 3.6% year on year (“YoY”), with
overall operations remaining solid.
Revenue from international markets① (excluding North America) was US$127.0 million,
representing an increase of 16.7% YoY. Across the region, revenues in APAC, Europe, and
Middle East and Africa were US$78.4 million, US$26.7 million, and US$16.8 million, with growth
of 19.1%, 12.1%, and 20.9% YoY, respectively. Revenue in North America was US$44.4 million,
representing a decrease of 21.6% YoY, while Canada recorded over 20.0% YoY growth,
pointing to partial regional recovery.
Medical Aesthetics revenue (excluding North America) was US$97.1 million, representing an
increase of 7.2% YoY.
Injectables revenue was US$22.2 million, representing an increase of 54.2% YoY and
accounting for 12.9% of total revenue, which consolidated its position as the Company’s second
growth pillar.
Gross profit margin was 56.7%, compared with 60.0% in the same period of 2025, primarily
attributable to shifts in geographic sales mix and product mix.
Net profit was US$1.1 million, compared with US$9.0 million in the same period of 2025. Net
profit margin was 0.6%, compared with 5.4% in the same period of 2025. The changes were
mainly driven by the Company’s investment in building the injectable business in China and
softer performance in North America, where the Company has proactively refined its business
model, execution setup, and cost base accordingly.
Adjusted net profit was US$5.0 million, compared with US$12.0 million in the same period of
2025. Adjusted net profit margin was 2.9%, compared with 7.2% in the same period of 2025.
Key Achievements
EBD Platforms: Sustained Momentum, Accelerated Localization
Sisram further deepened its core EBD technology expertise and strengthened its technological moat,
cementing its leadership footprint in the global medical aesthetics device market. The Company’s
flagship multi‑application platforms Alma Harmony and Hybrid family delivered consistent growth,
1
underpinned by versatile multi- technology functionality and well- validated clinical treatment
protocols. Solid market uptake and rising brand recognition attest to the long‑term durability and
worldwide competitiveness of Sisram’s EBD portfolio. In June 2026, Soprano Titanium was
successfully introduced in Thailand, rapidly earning recognition and favorable feedback from top‑tier
aesthetic clinics upon launch. This roll‑out also unlocked tangible commercial synergies between
EBD and injectables businesses, opening new avenues for cross‑category collaboration and mutual
value creation.
Drawing on its established global business foundation, Sisram stepped up regional execution across
APAC, fine- tuning its product portfolio and treatment offerings to address evolving market demands.
In July 2026, the Company expanded its regional footprint with two strategic launches: Titanium
Prime in Hong Kong SAR and the new EBD platform, “ 黑金牛奶光 ” (Black Gold Photofacial) in
Mainland China. These initiatives not only broadened Sisram’s regional product and treatment
ecosystem but also resonated with the growing consumer shift from standalone skin rejuvenation
toward long‑term, personalized skin health management.
Sisram also hit a landmark milestone under its China‑focused localization agenda. June 2026 saw
official commissioning of the Miyun, Beijing manufacturing facility, where the first locally assembled
Alma Rejuve unit came off the production line. This development constitutes a major leap forward
for the Company’s manufacturing capacity in China. Built upon field‑proven production workflows
and rigorous quality‑control systems inherited from the Israeli manufacturing base, the Beijing facility
enhances supply efficiency and product quality consistency, improving local product availability and
supporting Sisram’s long-term APAC growth ambitions.
Injectables: Rapid Growth, Differentiated Pipeline
The injectables business extended its strong 2025 track record, solidifying its standing as the
Company’s second growth pillar. Core product DAXXIFY achieved major commercial milestones in
Mainland China, with cumulative shipments to clinics surpassing 30,000 vials and distribution
reaching nearly 500 premium aesthetic clinics as of June 30, 2026. This early- phase performance
stems from proactive partner collaboration and structured clinical- training frameworks. To preserve
this positive trajectory, Sisram sharpened its focus on DAXXIFY’s premium brand positioning. The
Company partnered with leading benchmark clinics and deployed a full suite of standardized training,
refined front- end operational support, and tailored local injection protocols. These efforts boosted
clinical utilization and repeat purchase rates, consolidated the product’s leadership in the premium
botulinum toxin segment, and expanded channel penetration across Mainland China.
Profhilo, formulated with high concentration hyaluronic acid, has garnered widespread acclaim
among Thailand’s top aesthetic clinics, further sharpening Sisram’s competitive positioning across
APAC. Hallura, the innovative BDDE free HA filler, debuted in Israel during 2025 and is advancing
steadily through its global commercial roll out. Collectively, these advances embody Sisram’s
strategic priority to scale its injectables footprint across priority geographies, diversify its worldwide
product offerings and foster deeper cross divisional synergies.
AI-Powered Ecosystem: Market Traction, Global Expansion
The Company’s AI-enabled ecosystem continued to gain ground within pilot markets, supported by
strong customer retention and repeat-order levels consistently above industry benchmarks. Alma IQ,
2
the Company's personalized diagnostics device, was featured in Glamour's Beauty Innovator 2026
and recognized with the Best Use of AI for Skin award, validating the commercial merit of AI-powered
diagnostics and personalized skincare. Universkin by Alma, the Company's AI-enabled skincare
system, maintained robust momentum in the United States and has now launched in the DACH
region and Hong Kong SAR. Additional market introductions are slated for the second half of 2026,
advancing build-out of the fully integrated ecosystem spanning EBD, injectables, AI diagnostics, and
skincare.
OUTLOOK
Carrying forward solid operating traction from the first half, Sisram enters the second half of 2026
focused on driving steady revenue growth, prioritizing profitability recovery and cash conversion, and
enhancing operational efficiency across the board. The Company continues to refine its integrated
wellness ecosystem from diagnostics and treatment to ongoing care.
In China, Sisram will pursue phased roll- out for DAXXIFY by setting up benchmark clinic sites and
rolling out region- adapted injection protocols. In addition, the Company will accelerate sales of nextgeneration energy-based devices and unlock greater synergies between its EBD and injectables
businesses by integrating customer resources, medical education, and supply chain capabilities.
Sisram will also progressively expand production capacity at the Beijing facility to enhance delivery
performance, logistics capabilities, and after-sales service standards for both the local market and
the broader APAC region.
In North America, Sisram will prioritize performance stabilization and profitability recovery. By rolling
out new energy-based devices and treatment protocols that address evolving practitioner and patient
needs, while simultaneously driving operational efficiencies and right sizing its cost base, the
Company aims to restore its competitive edge and return to sustainable growth in the region.
Globally, Sisram will hone its commercial edge, capture upside within accessible product categories,
and bring next- generation EBD platforms and treatment protocols to market. The Company will also
fuse its AI- driven Alma IQ diagnostic system, Universkin by Alma professional skincare line, and
EBD platforms into a more cohesive ecosystem. Market- specific diagnostic solutions and treatment
concepts will be tailored to local clinical norms, regulatory regimes and consumer behaviors, while
AI- powered skincare offerings will enter fresh territories, widening Sisram’s global reach.
In parallel, the Company will actively pursue ecosystem- aligned investments, M&A opportunities,
licensing, and partnerships to bolster R&D competence and expand the product portfolio. These
initiatives aim to diversify the product pipeline and inject lasting momentum into Sisram’s mediumand long- term sustainable, high- quality growth.
MANAGEMENT COMMENTARY
Mr. Lior Dayan, Chairman of Sisram, said: “As consumers increasingly pursue long‑term,
personalized skin‑health management, the global medical‑aesthetics industry is evolving rapidly
away from standalone treatments toward comprehensive solutions encompassing diagnostic
assessment, combined treatment protocols and ongoing maintenance care. Drawing on its proven
3
leadership in EBD, Sisram has steadily constructed an integrated wellness ecosystem spanning
energy‑based devices, injectables, AI‑powered diagnostics and personalized skincare, which puts
the Company in a strong position to seize substantial medium‑to‑long‑term market opportunities.
Moving ahead, Sisram will keep advancing innovation and expanding its global footprint, strengthen
its foothold in core geographies, and further entrench its worldwide competitive advantages, to
deliver enduring long‑term value for practitioners, patients and shareholders alike.”
Mr. Eyal Ben David, CEO of Sisram, added: “During the first half of 2026, we posted sound
progress across our international markets and pressed ahead with the build‑out of our second growth
engine. Our flagship EBD platforms retained their global market leadership, a testament to the high
confidence leading practitioners place in our technologies and clinical results. DAXXIFY’s
commercial rollout in Mainland China gained meaningful positive traction. Together with the distinct
value propositions of Profhilo and Hallura, it has materially broadened our footprint within the
premium injectables segment, solidifying the portfolio as a potent second growth engine and driving
robust divisional performance. On operations, we further enhanced our R&D framework, optimized
resource allocation and improved cross‑functional collaboration to speed progress for key
development work and priority product pipelines. Going forward, we will keep EBD as our core
bedrock, while leveraging injectables as our secondary growth driver. With sharp focus on priority
markets including APAC and North America, we will accelerate commercial launches of core
products and treatment protocols, bringing more holistic, higher‑value integrated wellness solutions
to practitioners and patients.”
Mr. Jiahong Li, Co-CEO and CFO of Sisram, commented: “Notwithstanding persistent headwinds
in North America, we achieved 3.6% year‑on‑year revenue growth for the first half of 2026, backed
by solid performance from our international operations and injectables business. Second‑quarter
revenue accelerated both year‑on‑year and sequentially, illustrating the resilience inherent within our
diversified geographic and product‑category mix. On profitability, near‑term pressure largely stems
from softer US market results together with our strategic investments behind China‑based injectables
operations. We have already rolled out targeted remedial measures to address these short-term
challenges. Going forward, our second- half priorities revolve around cost discipline and operational
quality, with profitability recovery and cash conversion at the forefront, alongside company‑wide
efficiency drives. With a robust balance sheet and well‑defined strategic roadmap, we remain
confident in delivering sustainable, higher‑quality growth via both organic initiatives and external
opportunities, generating lasting value for our shareholders.”
①International markets refer to all markets globally, excluding North America.
About Sisram Medical Ltd
Sisram Medical Ltd (1696.HK) is a global leader in medical aesthetic solutions with over 25 years of
expertise in Energy-Based Devices (EBD). Built on a legacy of innovation and clinical excellence,
the Company’s synergistic ecosystem spans EBD technologies, injectables, diagnostics, and
complementary solutions. Serving customers in over 110 countries and regions, Sisram delivers
award-winning products that set new standards in safety, efficacy, and personalized aesthetic care
for millions of patients worldwide. Majority-owned by Fosun Pharma, Sisram has been listed on the
Main Board of the Hong Kong Stock Exchange since September 2017.
4